Testing a new drug for advanced cervical cancer after standard treatments
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is testing a new drug called SHR-A2102 against standard chemotherapy for people with advanced cervical cancer that has not responded to platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor). The goal is to see if the new drug works better and what side effects it may cause.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cervical cancer called squamous cell, adenocarcinoma, or adenosquamous carcinoma that cannot be cured with surgery or radiation.
- You have tried both platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor) and your cancer has not improved.
- You are willing to provide a sample of your tumor from a previous biopsy or surgery.
- Your cancer has at least one measurable tumor (as seen on scans like CT or MRI).
- You are physically active enough to care for yourself (ECOG score 0 or 1).
- Your major organs (like heart, liver, kidneys) are working well enough for you to safely take the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
This trial tests a new drug, SHR-A2102, against the usual treatments for people with advanced bladder cancer that has spread. It is for those whose cancer has worsened after platinum chemotherapy and immunotherapy.
This trial tests a new drug, SHR-2022, for people with advanced cancers that have not responded to other treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called SHR-A2102, alone or with other cancer treatments, for people with advanced solid tumors that haven't responded well to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug, SHR-A1811, that targets a protein called HER2 found on some cervical cancer cells. It's for women whose cervical cancer has returned or spread and is not responding to other treatments.
Hear when a new Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.